Initially, we verified by both real-time PCR and immunohistochemistry that NDRG2 was downregulated in human breast tumor tissue, underlining recent studies showing NDRG2 expression loss in the course of tumor progression. This evidence concerns the gene NDRG2 and neoplasm.